Diagnostic Development Services
High expression of seprase or fibroblast activation protein (FAP) has been shown to be an independent poor predictor of prognosis in lung, hepatocellular, and colon cancers. At Alfa Cytology, we are dedicated to the development of diagnostic methods targeting seprase (FAP) and actively promote research into innovative therapies for cancers, fibrotic diseases, and autoimmune diseases.
Introduction to Seprase (FAP)-Targeted Diagnostic
Seprase (FAP) is a type II integral membrane glycoprotein of the serine protease family that plays a role in fibrogenesis and ECM remodeling. It is overexpressed in a variety of tumor types, particularly in cancer-associated fibroblasts (CAFs) in the tumor microenvironment, while its expression is low in normal tissues, making it a potential target for tumor-specific imaging and therapy. Beyond tumors, seprase (FAP) may also provide valuable targets for imaging and treatment of inflammatory diseases.
Fig. 1 Cancer-associated fibroblast in the tumor microenvironment. CAF, cancer-associated fibroblasts; FAP, fibroblast activation protein. (Privé, B. M., et al. 2023)
Seprase (FAP)-Targeted Diagnostic Drug Development
The following are diagnostic drug development that target seprase (FAP), including but not limited to:
| Name | Indication | Company | NCT Number |
| FAP-2286 | Solid Tumors | Novartis | NCT04939610 |
| OncoFAP | Solid Tumors | Philogen | \ |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Alfa Cytology is a leader in the development of seprase (FAP)-targeted diagnostic methods, focusing on the discovery of novel FAP-responsive biomarkers and the development of targeted seprase (FAP) imaging services. We leverage our expertise and high-end equipment to advance the development of various disease diagnostics.
Multiple Diagnostic Development Services
Seprase (FAP)-Targeted Imaging Agent
Using advanced imaging modalities such as PET and SPECT, we provide seprase (FAP)-targeted imaging agent for improved detection and characterization of FAP-expressing tumors.
Theranostic Radiopharmaceuticals
Combining precision cancer care with today's most innovative radiopharmaceuticals, we deliver dual modality solutions for both diagnosis and therapy in FAP-expressing tumors.
Our Process Flow
Identify Your Needs
Schedule a Meeting
Attain Optimal Results
Choose Suitable Services
Get Tailored Plan
At Alfa Cytology, we leverage an extensive portfolio of innovative seprase (FAP)-targeted diagnostic methodologies to deliver precise medical solutions. We are a trusted partner in the development of seprase (FAP)-targeted diagnostics. Please contact us for more detailed information about how our services might best fit into your drug discovery and development program.
Reference
- Privé, B. M., et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. European journal of nuclear medicine and molecular imaging. 2023, 50(7): 1906–1918.
For research use only.